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Abstract
Background: Chronic cerebrospinal venous insufficiency (CCSVI) has recently been reported to be associated with
multiple sclerosis (MS). However, its actual prevalence, possible association with specific MS phenotypes, and
potential pathophysiological role are debated.
Method: We analysed the clinical data of 710 MS patients attending six centres (five Italian and one Canadian). All
were submitted to venous Doppler sonography and diagnosed as having or not having CCSVI according to the
criteria of Zamboni et al.
Results: Overall, CCSVI was diagnosed in 86% of the patients, but the frequency varied greatly between the
centres. Even greater differences were found when considering singly the five diagnostic criteria proposed by
Zamboni et al. Despite these differences, significant associations with clinical data were found, the most striking
being age at disease onset (about five years greater in CCSVI-positive patients) and clinical severity (mean EDSS
score about one point higher in CCSVI-positive patients). Patients with progressive MS were more likely to have
CCSVI than those with relapsing-remitting MS.
Conclusion: The methods for diagnosing CCSVI need to be refined, as the between-centre differences, particularly
in single criteria, were excessively high. Despite these discrepancies, the strong associations between CCSVI and MS
phenotype suggest that the presence of CCSVI may favour a later development of MS in patients with a lower
susceptibility to autoimmune diseases and may increase its severity.
Background
Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease of the central nervous system with an auto-
immune pathogenesis which has been the subject of
thousands of clinical and experimental studies [1-3].
Although the causes triggering the autoimmune process
are not entirely clear, it is generally accepted that they
lie in the interplay between genetic and environmental
factors [4-6]
Recently a new “actor” has appeared on the scene,
namely, chronic cerebrospinal venous insufficiency
(CCSVI), a condition which may be either mostly
genetically determined or acquired [7-9]. CCSVI is char-
acterised by multiple stenoses of the extracranial venous
draining pathways, i.e. the internal jugular veins and the
Azygous veins, which lead to collateral formation, altera-
tion of the blood-brain barrier, and accumulation of
iron, which itself could trigger and maintain the autoim-
mune cascade [7,9,10]. Some well known, but poorly
explained, aspects of MS, such as the perivenular loca-
tion of the lesions, the neurodegeneration and the com-
mon presence of iron deposits, seem to fit well with this
hypothesis.
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actual existence of CCSVI in MS, and its putative patho-
genetic role, or about the most efficient tool for diag-
nosing it [11,12]. Most studies finding significant
differences in the prevalence of CCSVI between MS
patients and controls used a venous sonographic
method in accordance with Zamboni’so r i g i n a lr e p o r t
[13]. However, Doepp et al. [14,15], adopting a different
sonographic approach, did not find evidence of CCSVI
in a group of 56 MS patients. In two further studies, the
pathogenetic role of CCSVI was challenged, as the con-
dition was found to be linked only to more advanced
disease [16], or to be present only in a very limited pro-
portion (16%) of patients with clinically isolated syn-
drome [17]. Even less explored is the possibility that MS
patients with CCSVI, as opposed to those without, have
a characteristic disease ‘phenotype’. The finding of phe-
notypic associations could prove particularly important,
steering further pathophysiological research and making
it possible to refine a putative ‘vascular model’ to be
integrated with the existing autoimmune one.
In the present research, whose main aims were to
assess the variability of CCSVI data between the centres
and to seek to identify consistent relations with clinical
aspects, we analysed the ‘basic’ clinical data of MS
patients from six MS centres, five Italian and one Cana-
dian. All the patients were submitted to venous echo-
colour-Doppler examinations according to the proce-
dure used by Zamboni et al.
Methods
The centres in which the echo-colour-Doppler examina-
tions were performed are:
Centre 1: Department of Public Health and Neuros-
ciences, IRCCS “C. Mondino National Institute of
Neurology” Foundation, University of Pavia, Italy
Centre 2: Barrie Vascular Imaging, Barrie Ontario,
Canada
Centre 3: Hospital of Civitanova, Marche, Italy
Centre 4: Department of Neurosciences, Federico II
University of Naples, Italy
Centre 5: Multiple Sclerosis Centre, IRCCS Don
Gnocchi, Milan, Italy
Centre 6: CCSVI Project, “Policlinico di Monza”,
Italy
Patients
We collected data of 805 patients from the above cen-
tres, all patients signed a consent form. All had a diag-
nosis of MS according to McDonald’s revised criteria
[18] and all were submitted to Doppler sonography in
the period between 2 January 2010 and 17 January 2011.
No particular inclusion criteria were used, apart from a
diagnosis of MS. In this way, we obtained six sets of
‘consecutive’ assessments of regularly monitored patients
who had asked to undergo the procedure.
Of the original 805 patients, 95 were excluded because
no data could be obtained regarding their form of MS.
Therefore, the final study sample comprised 710
patients (466 females and 244 males).
The following clinical data were considered: sex, age
at time of Doppler evaluation, age at disease onset, dis-
ease duration at time of Doppler evaluation, and
Expanded Disability Status Scale (EDSS) score at time of
Doppler evaluation. From these data the Multiple
Sclerosis Severity Score (MSSS) score was computed,
which is a validated measure of disease severity com-
puted from disability (EDSS) and disease duration data
[19].
The echo-colour-Doppler examinations of cerebrosp-
inal venous drainage were performed by nine different
trained ultrasound operators using three different ultra-
sound systems:
- ECD Esaote-Biosound MyLabVinco 25 scanner
equipped with a 3.5-10 MHz linear transducer and a
5.0-8.0 MHz microconvex transducer, both for extra-
cranial measurements, and a 2.0-3.3 MHz phased
array probe for transcranial analysis (Centres 1,
3,5,6)
- P5 General Electric ultrasound machine equipped
with a linear probe 3.5-10 MHz for extracranial
examination and a 2.0-3.0 MHz sector probe for
transcranial examination (Centre 2);
- Philips iU22 system equipped with a 3.0-9.0 MHz
linear wide-band transducer, a 5.0-8.0 MHz micro-
convex probe, and a 1.0-5.0 MHz phased array tran-
scranial probe (Centre 4).
Each subject was investigated first in supine position
and then in sitting position using a tilt chair. All were
scanned following the Zamboni protocol for diagnosis of
CCSVI, which is based on the detection of five para-
meters:
1 - Reflux in the internal jugular veins (IJVs) and/or
vertebral veins (VVs) in sitting and supine posture.
2 - Reflux in the intracranial veins. Reflux is defined
as a reversal of flow direction during the inspiratory
and expiratory phase during normal breathing with
mouth closed. The transcranial colour-coded duplex
sonography (TCCD) studies were carried out using
one of two different approaches: the classic trans-
temporal window or the transcondylar window.
The classic transtemporal window was used by one
centre (Centre 4 - 118 MS patients), evaluating flow
direction in the Rosenthal vein and transverse sinus,
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the transcondylar window, which assesses the direc-
tion of flow in the cavernous and petrosal sinuses.
The transducer was placed at the level of the man-
dibular condyle, sloping the tail approximately 10
degrees downwards. The insonation depth was set at
11 cm.
3 - B-mode evidence of abnormalities in the IJVs,
such as stenoses, malformed valve, annulus, septums,
etc.
4 - Flow not Doppler-detectable in IJVs and/or VVs
despite numerous deep breaths.
5 - Reverted postural control of the main cerebral
venous outflow pathways, detected by measuring the
difference in IJV cross-sectional area (CSA) between
the supine and upright positions.
ΔCSA in the IJV, obtained by subtracting the CSA
measured in sitting position from that measured in
supine position, is a positive value in normal sub-
jects. A negative ΔCSA value indicates loss of pos-
tural control of the predominant outflow route in
the supine position.
This parameter was assessed in B-mode in transver-
sal access, at the J2 point which corresponds to the
level of the thyroid gland, and carefully avoiding any
compression of the vessel by the probe.
Statistical analysis
The Kolmogorov-Smirnoff test was used to check the
distribution of quantitative variables for deviation from
n o r m a l .D a t aw e r es u b m i t t e dt ou n i v a r i a t ea n a l y s i so f
variance (UNIANOVA), chi-square statistics (CROSS-
TABS) and logistic regression analysis using a stepwise
forward procedure (NOMREG). The statistical analysis
was conducted using SPSSPC+ software.
Results
Table 1 summarises the clinical data of the MS patients
from the six participating centres. All parameters
showed highly significant differences (p < 0.001)
between the centres, with the exception of disease
duration (p = 0.022). The between-centre differences in
mean values of quantitative clinical data could not be
attributed entirely to different distributions of MS
forms, since they were also present when the different
MS forms were analysed separately (with the exception
of age and EDSS score in the primary progressive group,
which did not show significant differences between the
centres).
Table 2 shows the proportions of patients, from the
six centres, who fulfilled each of the single CCSVI cri-
teria and who had a CCSVI diagnosis (i.e. fulfilled at
least two CCSVI criteria). The between-centre differ-
ences in the percentages of presence/absence of each of
the five CCSVI criteria, as well as of CCSVI diagnosis,
were all highly significant (p < 0.001).
Table 3 shows the distribution of all the possible com-
binations of 2 or more criteria present in the patients of
the study. It appears that the more frequent combina-
tions are: 1+3, 1+2+3, 1+3+5 and 1+3+4+5, which
together represent thirty-five percent of cases.
The table 4 shows the distribution of the different cri-
teria in patients with negative CCSVI. In particular, in
this group we note that in 23 patients Doppler examina-
tion showed the presence of B-mode anomalies (positiv-
ity of the third criterion) in the absence of
hemodynamic’s flow consequences in the vein, mean
while 26 patients had hemodynamic’sf l o wa n o m a l i e si n
the jugular veins or vertebral (positivity of the first or
fourth criterion), in the absence of anatomical abnorm-
alities. 28 patients (4% of the study population) showed
no criterion.
Given the high between-centre differences both in the
presence of CCSVI (found in 86.2% of patients overall,
range: 74%-96%) and in the mean values of the patients’
clinical parameters, the presence of possible associations
between CCSVI and clinical data was tested by logistic
regression analysis using a stepwise forward procedure,
entering first the centre defining factor and subsequently
the clinical data.
The final model proved to be adequate (chi-square (7
df) = 89.5; p < 0.001). The parameters included in the
f i n a lm o d e lw e r e( i na d d i t i o nt ot h ec e n t r ed e f i n i n g
Table 1 Clinical data of MS patients from the 6 MS centres; counts, means and (standard deviations)
MS centre 1 2 3 4 5 6 All centres
RR/SP/PP 104/37/7 97/68/44 74/34/8 62/34/22 19/28/2 32/26/12 388/227/95
Age 43(10) 49(11) 43(10) 45(10) 43(10) 44(11) 45(11)
Age at onset 31(10) 36(10) 32(10) 32(8) 29(10) 34(10) 33(10)
Disease duration 12(8) 14(8) 11(8) 13(8) 14(9) 10(6) 12(8)
EDSS 3.5(2.3) 5(2.3) 4.4(2.2) 5.7(1.5) 4.5(1.9) 4.4(2.2) 4.4(2.2)
MSSS 4.1(2.9) 6(2.7) 5.4(2.7) 4.8(1.7) 6.1() 5.3(2.6) 5.3(2.6)
p < 0.001 for all parameters except disease duration (p = 0.022).
RR: relapsing-remitting; SP: secondary progressive; PP: primary progressive
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an older age at onset both indicated a higher probability
of CCSVI being present.
The parameter estimates are shown in table 5.
Table 6 reports the mean values of EDSS and age at
disease onset (the two variables selected by logistic
regression) in patients with and in those without CCSVI
from each centre. Overall, the frequency of CCSVI
increased with increasing EDSS values (see Figure 1:
chi-square for linear association 17.6, 1 df; p < 0.001).
Within-centre analyses revealed the following differ-
ences: MSSS was significantly higher in CCSVI-positive
patients from Centres 2,5 and 6; age at disease onset
was greater in CCSVI-positive subjects from Centre 4.
With regard to the different types of MS, the following
percentages of patients, in the whole sample, were
found to be CCSVI-positive: relapsing-remitting (RR)
82%, secondary progressive (SP) 91%, primary progres-
sive (PP) 92% (p < 0.001). With the exception of Centre
6, progressive patients (i.e. SP+PP) were more frequently
CCSVI-positive, the difference reaching statistical signifi-
cance in Centres 3 and 4 (a borderline significant differ-
ence, p = 0.055, was also found in Centre 2).
The associations between clinical variables and CCSVI
were very high in the RR subgroup (see table 7); in the
other two subgroups (SP and PP) no variable reached
statistical significance, even though the differences in
mean values tended, without exception, in the same
direction as those recorded in the RR subgroup. We
also performed a logistic regression analysis using a
slightly different criterion to define the presence of
CCSVI, i.e. fulfilment of at least three of the five CCSVI
criteria instead of only two. Sixty-three percent of the
patients could be diagnosed as CCSVI-positive using
this cutoff. This model identified the same explanatory
variables (age at disease onset and EDSS), fitted in a
similar way.
Discussion
In the limited literature available on this topic, CCSVI
has been found in different proportions of MS subjects
[20-22]. In the majority of studies, however, the fre-
quency of CCSVI-positive patients exceeded that of
CCSVI-positive healthy controls, suggesting that some
link with MS (and possibly with other conditions) may
exist.
H o w e v e r ,t h ep r e v a l e n c eo fC C S V I - p o s i t i v ep a t i e n t s
varies greatly between centres, a fact confirmed by our
Table 2 Percentages of positive CCSVI diagnoses and of
positive single CCSVI criteria recorded at each MS centre
Doppler
abnormality
MS centre
1 2 3 4 5 6 All centres
Crit 1+ % 55 94 77 60 82 74 75
Crit 2+ % 49 26 46 29 80 91 45
Crit 3+ % 69 86 89 70 84 87 80
Crit 4+ % 21 46 36 37 29 19 34
Crit 5+ % 24 86 18 5 18 23 38
CCSVI+ % 77 96 91 74 82 94 86
p < 0.001 for all parameters
Table 3 Number of CCSVI+ patients according to the specific combinantion of Zamboni’s Criteria.
Patients with:
2 positive Criteria Crit1+ Crit2+ Crit3+ Crit4+
Crit2+ 11
Crit3+ 75 36
Crit4+ 10 7 19
Crit5+ 9 2 4 4
3 positive Criteria Crit12+ Crit13+ Crit14+ Crit23+ Crit24+
Crit3+ 109
Crit4+ 4 39 10
Crit5+ 9 78 5 5 8
4 positive Criteria Crit1234+ Crit1235+ Crit1245+ Crit1345+ Crit2345+
22 37 9 63 0
5 positive Criteria Crit12345+
35
Table 4 Clinical characteristics of the 98 CCSVI negative
patients.
Crit1+ Crit2+ Crit3+ Crit4+ Crit5+ anyCrit+
n 2 01 92 36 2 7 0
EDSS 3,1/3,4 3,5/2,8 3,4/3,5 3,2/4,7 3,3/4,8 3,1/3,5
MSSS 4,0/4,3 4,0/4,1 4,0/4,1 4,0/4,6 4,0/6,4 3,4/4,3
age at onset 28/32 29/31 30/26 29/31 29/26 29/29
n: number of subjects with single positive criteria;
EDSS, MSSS and age at onset: mean values of CCSVI negative patients with
single negative/positive Zamboni Criteria. No comparison reaches statistical
significance.
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study, including the use of different techniques, the rela-
tive unreliability of the test and the differences in the
patient populations. The between-centre variability was
found to be even higher when considering the single
CCSVI criteria, although the third and first criteria
tended to occur with greater frequency than the other
three. Similar figures (even if with slightly lower percen-
tages) were recently reported in the largest single center
study by Zivadinov et al. [22]. We believe that the high
frequency of the third criterion in MS patients is a parti-
cularly significant finding, since this criterion is related
to direct visualisation of a venous anatomical abnormal-
ity, and should therefore be less operator-dependent.
Although there were patients in whom flow abnormal-
ities were seen in the absence of anatomical alterations,
in these cases there is always a doubt that the B-mode
anomalies were not seen. Since all the operators taking
part in our study were trained in the method of Zam-
boni et al. in order to reduce inter-observer differences
[23], the considerable variability in our data could be
explained by the use of different equipment.
Differences in patient characteristics could account for
another portion of the between-centre variability in our
CCSVI findings. Indeed, higher frequencies of CCSVI
were recorded in the centres which had the more
severely affected patients. However, the relevance of this
finding is not limited to the fact that it could partially
explain the between-centre variability. Indeed, the asso-
ciation between CCSVI and EDSS (demonstrated by the
logistic regression analysis) not only accounted for over-
all between-centre differences (possibly related to tech-
nical or other factors), but was also confirmed in the
within-centre analyses, which showed consistently
higher EDSS values in CCSVI-positive as opposed to
CCSVI-negative subjects (the overall difference, corre-
sponding to about one EDSS point, reached statistical
significance in three centres). This finding, already
reported by others [24], was reinforced in our study by
the generally higher MSSS scores in CCSVI-positive
patients.
The other variable consistently associated with CCSVI
was age at disease onset, and this constituted another
relevant finding: the CCSVI-positive patients were about
five years older than the CCSVI-negative ones at disease
onset. This association, to our knowledge never pre-
viously reported (Zivadinov et al. [22] reported only a
slight difference in the frequency of CCSVI in a small
group of paediatric MS), deserves particular attention. It
could not be attributed only to differences in clinical
course - PP subjects have generally a later disease onset
and also more frequently present CCSVI - since it was
also prominent in the RR subgroup. The association of
older age at onset and a worse course in RR MS patients
has been reported in a population-based study [25].
Moreover, a study on the clustering of multiple sclerosis
recently highlighted the possible effect of ‘exogenous’
Table 5 Parameter estimates from the final model of the logistic regression analysis (stepwise forward procedure)
performed using CCSVI as the dependent variable.
Parameter Estimates
CCSVI
a B Std Error Wald df Sig. Exp(B) 95% Confidence interval for Exp(B)
Lower limit Upper limit
1 Intercept 1.204 1.153 1.089 1 .297
[CENTRE = 1] -2.199 1.056 4.338 1 .037 .111 .014 .878
[CENTRE = 2] .356 1.190 .089 1 .765 1.427 .139 14.695
[CENTRE = 3] -.183 1.260 .021 1 .885 .833 .070 9.844
[CENTRE = 4] -2.534 1.056 5.764 1 .016 .079 .010 .628
[CENTRE = 5] -2.217 1.157 3.671 1 .055 .109 .011 1.052
[CENTRE = 6] 0
b .. 0 . . . .
EDSS .228 .080 8.066 1 .005 1.256 1.073 1.470
Age at onset .047 .018 6.778 1 .009 1.049 1.012 1.087
The centre-defining variable (5 df) was forced to enter. Positive B values indicate a higher probability of CCSVI+.
Table 6 Mean values of EDSS and age at onset (/n) in
CCSVI+ and CCSVI- patients in each MS centre.
MS
centre
CCSVI 1 2 3 4 5 6 All
centres
Age at
onset
+ 31/
112
36/
200
32/
105
33/
87
30/
40
34/
66
34/610
- 28/34 31/9 28/11 28/
31
29/9 31/4 29/98
p < ns ns ns 0.01 ns Ns 0.001
EDSS + 3.6/
112
5.1/
200
4.3/
105
4.4/
87
6.0/
40
4.6/
66
4.5/610
- 3.3/
36
1.7/9 2.3/
11
3.6/
31
4.4/9 1.5/4 3.4/98
p < ns 0.01 ns ns 0.01 ns 0.001
The levels of significance are also reported.
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Indeed, also taking these observations into account, a
putative model integrating ‘autoimmune’ and ‘vascular’
pathogenesis could fit our findings. In this framework,
CCSVI could act as an ‘exogenous’ factor increasing
mean age at onset by favouring the development of the
disease in older subjects with a relatively low susceptibil-
ity to autoimmune diseases, some of whom would possi-
b l yo t h e r w i s en e v e rb ei l l .T h er e c e n tf i n d i n gt h a t
CCSVI is not linked to HLA DRB1*1501 status [27]
confirms that venous insufficiency may act indepen-
dently of the ‘autoimmune trait’. On the contrary, these
same findings are more difficult to integrate into an
alternative model in which CCSVI is considered a sec-
ondary phenomenon.
Our data, while relatively robust due to the multicen-
tre approach, need to be confirmed by replication and
our hypothesis further evaluated. For instance, according
to our model MS subjects without CCSVI should show
a higher prevalence of MS-associated autoimmune dis-
orders (i.e. thyroiditis or uveitis) and respond better to
immunomodulating therapy.
Our data confirm that CCSVI is linked to MS, and
tend to support the hypothesis that it could be a factor
favouring disease development in relatively low-predis-
posed subjects and possibly a factor increasing disease
severity. Every effort should be made to increase the
reliability of the existing diagnostic techniques and to
develop other ones, as the inter-centre differences
observed in this and in other studies seem to be unac-
ceptably high. The possible safety and efficacy of vascu-
lar intervention procedures should be assessed in
blinded trials. Our data seem to suggest that the power
of pilot interventional studies would be increased by
selecting patients with a relatively older age at disease
onset.
Conclusion
This multicentre study confirms that a high proportion
MS patients have CCSVI, as assessed by venous Doppler
sonography. The relative high between-centre variability,
particularly of single CCSVI criteria suggests that search
for more reliable diagnostic procedures should be
encouraged. The finding of significant relations between
CCSVI and clinical aspects of MS testifies that CCSVI
and MS are related entities. Nevertheless the signifi-
cance of this relation is far from being assessed and
Table 7 Mean values of clinical parameters in the RR
subgroup.
Age Age at onset Disease duration EDSS MSSS
CCSVI + 42 32 10 3.2 4.4
CCSVI - 39 27 11 2.5 3.2
p < 0.05 0.001 ns 0.001 0.001
The levels of significance are also reported.
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Figure 1 Percentages of CCSVI-positive (CCSVI+) patients according to their EDSS score at the time of Doppler evaluation.
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research is needed.
Limitations of Our Study
Our study has several limitations. First, is the lack of
healthy controls (who were not available for each cen-
ter); for this reason the main objective of the study was
the correlation of the results with the clinical fenotypes
of MS, and not the prevalence of CCSVI among the
healthy and the MS population.
Second, the study was not blinded; although authors
who performed the Doppler studies were not involved
in the clinical management of the patients and were not
aware of the clinical forms, the investigators knew that
the subjects were MS patients.
However, we do not think the above limitations signif-
icantly compromise the validity of our findings.
Author details
1Department of Public Health and Neurosciences, IRCCS “C. Mondino
National Institute of Neurology” Foundation, University of Pavia, Italy.
2Interdepartmental Research Centre on Multiple Sclerosis, “C. Mondino
National Institute of Neurology” Foundation, Pavia Italy.
3Department of
Neurology and Psychiatry and Department of Neurosciences, Sapienza
University of Rome, Italy.
4Multiple Sclerosis Centre, IRCCS Don Gnocchi,
Milan, Italy.
5CCSVI Project, “Policlinico di Monza”, University of Milan, Italy.
6Hospital of Civitanova, Marche, Italy.
7Department of Neurosciences
Federico II, University of Naples, Italy.
8Barrie Vascular Imaging, Barrie Ontario,
Canada.
9Department of Neurosciences, Ospedale Circolo, University of
Varese, Italy.
Authors’ contributions
SB and RB equally contributed to conception and design, analysis and
interpretation of data; drafting the manuscript, Critical revision of the paper,
for important intellectual content. The first draft was written primarily by AR
with some sections by GV, and extensively discussed, re-worked and edited
by SB and RB. The statistical analysis was performed by AR. PC, MF, AG, MM,
VB, SM and GB made substantial contributions to the study’s conception
and design. GV, ECT, EG, MA, LM, DM, CQ and AL contributed to acquisition
of data. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 May 2011 Accepted: 26 October 2011
Published: 26 October 2011
References
1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple
sclerosis. N Engl J Med 2000, 343:938-52.
2. Courtney AM, Treadaway K: Remington G, Frohman E: Multiple sclerosis.
Med Clin North Am 2009, 93:451-76, ix-x.
3. Frohman EM, Racke MK, Raine CS: Multiple sclerosis–the plaque and its
pathogenesis. N Engl J Med 2006, 354:942-55.
4. Ebers GC: MS and autoimmune disorders. Neurogenetics 2009, 10:1-3.
5. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis.
Part I: the role of infection. Ann Neurol 2007, 61:288-99.
6. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis.
Part II. Noninfectious factors. Ann Neurol 2007, 61:504-13.
7. Zamboni P: The big idea: iron-dependent inflammation in venous
disease and proposed parallels in multiple sclerosis. J R Soc Med 2006,
99:589-93.
8. Zamboni P, Consorti G, Galeotti R, et al: Venous collateral circulation of
the extracranial cerebrospinal outflow routes. Curr Neurovasc Res 2009,
6:204-12.
9. Singh AV, Zamboni P: Anomalous venous blood flow and iron deposition
in multiple sclerosis. J Cereb Blood Flow Metab 2009, 29:1867-78.
10. Zivadinov R, Schirda C, Dwyer MG, et al: Chronic cerebrospinal venous
insufficiency and iron deposition on susceptibility-weighted imaging in
patients with multiple sclerosis: a pilot case-control study. Int Angiol
2010, 29:158-75.
11. Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den
Berg R, Uitdehaag BM, Polman CH, Barkhof F: J No association of
abnormal cranial venous drainage with multiple sclerosis: a magnetic
resonance venography and flow-quantification study. Neurol Neurosurg
Psychiatry 2011, 82(4):429-35.
12. Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G, Dall’ara S,
Bartolomei I, Salvi F: The value of cerebral Doppler venous
haemodynamics in the assessment of multiple sclerosis. J Neurol Sci
2009, 15(282):21-7.
13. Zamboni P, Galeotti R, Menegatti E, et al: Chronic cerebrospinal venous
insufficiency in patients with multiple sclerosis. J Neurol Neurosurg
Psychiatry 2009, 80:392-9.
14. Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ: No
cerebrocervical venous congestion in patients with multiple sclerosis.
Ann Neurol 2010, 68:173-83.
15. Zamboni P: Regarding “No cerebrocervical venous congestion in patients
with multiple sclerosis. Intraluminal jugular septation”. Ann Neurol 2010,
68(6):969.
16. Yamout B, Herlopian A, Issa Z, et al: Extracranial venous stenosis is an
unlikely cause of multiple sclerosis. Mult Scler 2010, 16:1341-8.
17. Baracchini C, Perini P, Calabrese M, Causin F, Rinaldi F, Gallo P: No evidence
of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.
Ann Neurol 2011, 69:90-9.
18. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple
sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005,
58:840-6.
19. Roxburgh RH, Seaman SR, Masterman T, et al: Multiple Sclerosis Severity
Score: using disability and disease duration to rate disease severity.
Neurology 2005, 64:1144-51.
20. Ghezzi A, Comi G, Federico A: Chronic cerebro-spinal venous insufficiency
(CCSVI) and multiple sclerosis. Neurol Sci 2011, 32:17-21.
21. Mayer CA, Pfeilschifter W, Lorenz MW, et al: The perfect crime? CCSVI not
leaving a trace in MS. J Neurol Neurosurg Psychiatry 2011, 82:436-440.
22. Zivadinov R, Marr K, Cutter G, Ramanathan M, Benedict RH, Kennedy C,
Elfadil M, Yeh AE, Reuther J, Brooks C, Hunt K, Andrews M, Carl E,
Dwyer MG, Hojnacki D, Weinstock-Guttman B: Prevalence, sensitivity, and
specificity of chronic cerebrospinal venous insufficiency in MS. Neurology
2011.
23. Menegatti E, Genova V, Tessari M, et al: The reproducibility of colour
Doppler in chronic cerebrospinal venous insufficiency associated with
multiple sclerosis. Int Angiol 2010, 29:121-6.
24. Weinstock-Guttman B, Cutter G, Marr K, Hojnacki D, Ramanathan M,
Benedict RHB, Morgan C, Yeh EA, Carl E, Kennedy C, Reuther J, Brooks C,
Elfadil M, Andrews M, Zivadinov R: Clinical correlates of chronic
cerebrospinal venous insufficiency in multiple sclerosis. Multiple Sclerosis
2010, 16(Supplement 10):S224.
25. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F, LORSEP Group:
Natural history of multiple sclerosis in a population-based cohort. Eur J
Neurol 2008, 15:916-21.
26. Pugliatti M, Cossu P, Sotgiu S, Rosati G, Riise T: Clustering of multiple
sclerosis, age of onset and gender in Sardinia. J Neurol Sci 2009, 286:6-13.
27. Weinstock-Guttman B, Zivadinov R, Cutter G, et al: Chronic Cerebrospinal
Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in
Multiple Sclerosis Patients. PLoS One 2011, 6:e16802.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/132/prepub
doi:10.1186/1471-2377-11-132
Cite this article as: Bastianello et al.: Chronic cerebrospinal venous
insufficiency in multiple sclerosis: clinical correlates from a multicentre
study. BMC Neurology 2011 11:132.
Bastianello et al. BMC Neurology 2011, 11:132
http://www.biomedcentral.com/1471-2377/11/132
Page 7 of 7